Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Jazz Pharmaceuticals PLC has received a consensus recommendation of "Moderate Buy" from analysts, with two hold ratings and fourteen buy ratings among sixteen ratings firms.
• The average one-year price target for Jazz Pharmaceuticals is approximately $178.67, with recent target prices from analysts ranging as high as $205.00.
• In its latest quarterly earnings report, Jazz Pharmaceuticals missed the consensus earnings estimate by $2.64, reporting earnings per share of ($8.25) despite revenue meeting expectations at $1.05 billion.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $178.6667.

Several equities analysts recently commented on JAZZ shares. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price on the stock. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th.

Jazz Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ JAZZ opened at $128.53 on Wednesday. The stock has a market capitalization of $7.80 billion, a P/E ratio of -19.10, a PEG ratio of 8.05 and a beta of 0.24. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $148.06. The firm's 50 day simple moving average is $117.54 and its two-hundred day simple moving average is $116.81. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the firm posted $5.30 earnings per share. The company's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the sale, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This trade represents a 1.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Hurley Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $25,000. Elequin Capital LP grew its stake in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after purchasing an additional 119 shares during the last quarter. Spire Wealth Management grew its stake in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 161 shares during the last quarter. Finally, Picton Mahoney Asset Management boosted its holdings in Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after acquiring an additional 269 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.